Clinical effect of rituximab as early administration for refractory thrombotic thrombocytopenic purpura associated with connective tissue diseases

References

• Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc. 1924;24:21.
   Google Scholar
• Amorosi EL. Ultamann Thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45:139–159.
   Web of Science ®Google Scholar
• Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600.
   PubMed Web of Science ®Google Scholar
• Afford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120:556–573.
   Web of Science ®Google Scholar
• Sadler JE, Moake JL, Miyata T, et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2004;2004:407–423.
   Google Scholar
• Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393–397.
   PubMed Web of Science ®Google Scholar
• Fujikawa K, Suzuki H, McMullen B, et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662–1666.
   PubMed Web of Science ®Google Scholar
• Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–41063.
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Yoshioka A, Park YD, et al. Upshaw–Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol. 2001;74:101–108.
   PubMed Web of Science ®Google Scholar
• Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–494.
   PubMed Web of Science ®Google Scholar
• Furlan M, Robles R, Solenthaler M, et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998;91:2839–2846.
   PubMed Web of Science ®Google Scholar
• Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Yagi H, Ishizashi H, et al. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol. 2004;41:68–74.
   PubMed Web of Science ®Google Scholar
• Matsuyama T, Kuwana M, Matsumoto M, et al. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost. 2009;102:371–378.
   PubMed Web of Science ®Google Scholar
• Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara medical university during 1998–2008. Inter Med. 2010;49:7–15.
   PubMed Web of Science ®Google Scholar
• Mori Y, Wada H, Gabazza EC, et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion. 2002;42:572–580.
   Web of Science ®Google Scholar
• Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60–68.
   PubMed Web of Science ®Google Scholar
• Zheng XL, Kaufman RM, Goodnough LT, et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043–4049.
   PubMed Web of Science ®Google Scholar
• Böhm M, Betz C, Miesbach W, et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol. 2005;129:644–652.
   PubMed Web of Science ®Google Scholar
• Levandovsky M, Harvey D, Lara P, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. J Hematol Oncol. 2008;1:23.
   Web of Science ®Google Scholar
• Jang MJ, Chong SY, Kim IH, et al. Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience. Int J Hematol. 2011;93:163–169.
   Web of Science ®Google Scholar
• Kim JW, Kim I, Oh KH, et al. Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the 10-year experience of a single center. Hematology. 2011;16:73–79.
   PubMed Web of Science ®Google Scholar
• Shah AA, Higgins JP, Chakravarty EF. Thrombotic microangiopathic hemolytic anemia in a patient with SLE: diagnostic difficulties. Nat Clin Pract Rheumatol. 2007;3:357–362.
   Google Scholar
• Kamiya K, Kurasawa K, Arai S, et al. Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol. 2010;20:81–85.
   PubMed Web of Science ®Google Scholar
• Niewold TB, Alpert D, Scanzello CR, et al. Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. J Rheumatol. 2006;33:1194–1196.
   PubMed Web of Science ®Google Scholar
• Limal N, Cacoub P, Sène D, et al. Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus. 2008;17:69–71.
   Web of Science ®Google Scholar
• Letchumanan P, Ng HJ, Lee LH, et al. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford). 2009;48:399–403.
   PubMed Web of Science ®Google Scholar
• Kameda T, Dobashi H, Kittaka K, et al. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment. Clin Rheumatol. 2007;26:2159–2162.
   PubMed Web of Science ®Google Scholar
• Kawano N, Yokota-Ikeda N, Yoshida S, et al. Therapeutic modality of 11 patients with TTP in a single institution in Miyazaki from 2000 to 2011. Intern Med. 2013;52:1883–1891.
   PubMed Web of Science ®Google Scholar
• Miyakawa Y, Imada K, Ichinohe T, et al. Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy. Int J Hematol. 2016;104:228–235.
   PubMed Web of Science ®Google Scholar
• Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323–335.
   PubMed Web of Science ®Google Scholar
• Kasper CK, Aledort L, Aronson D, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:612.
   PubMedGoogle Scholar
• Kato S, Matsumoto M, Matsuyama T, et al. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006;46:1444–1452.
   PubMed Web of Science ®Google Scholar
• Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med. 2010;49:7–15.
   PubMed Web of Science ®Google Scholar
• Scully M, McDonald V, Cavenagh JD, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute aquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746–1753.
   PubMed Web of Science ®Google Scholar
• McDonald V, Manns K, Mackie IJ, et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:1201–1208.
   PubMed Web of Science ®Google Scholar
• Fujibayashi T, Sugai S, Miyasaka N, et al. Revised Japanese criteria for Sjögren’s syndrome (1999): availability and validity. Mod Rheumatol. 2004;14:425–434.
   PubMedGoogle Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
   PubMed Web of Science ®Google Scholar
• Gitlow S, Goldmark C. Generalized capillary and arteriolar thrombosis. Report of two cases with a discussion of the literature. Ann Intern Med. 1939;13:1046–1067.
   Google Scholar
• Sato T, Hanaoka R, Ohshima M, et al. Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: observations in a single hospital. Clin Exp Rheumatol. 2006;24:454–455.
   PubMed Web of Science ®Google Scholar
• Caramazza D, Quintini G, Abbene I, et al. Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome. Blood Transfus. 2010;8:203–210.
   PubMed Web of Science ®Google Scholar
• Asamiya Y, Moriyama T, Takano M, et al. Successful treatment with rituximab in a patient with TTP secondary to severe ANCA-associated vasculitis. Intern Med. 2010;49:1587–1591.
   Web of Science ®Google Scholar
• Kosugi S, Matsumoto M, Ohtani Y, et al. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol. 2005;81:433–436.
   Web of Science ®Google Scholar
• Froissart A, Buffet M, Veyradier A, French Thrombotic Microangiopathies Reference Center, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40:104–111.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Bennett CL, Isonishi A, et al. Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One. 2012;7:e33029.
   PubMed Web of Science ®Google Scholar